Logo

Louis Drapeau

Feb 22, 2007
Premium
Bio-Rad has appointed Louis Drapeau to the company’s board of directors.
 
Drapeau will also serve on the board’s audit committee.
 
He is currently CFO of Nektar Therapeutics, a drug-development firm that recently named former Sirna Therapeutics head Howard Robin as its president and CEO.
 
Previously, Drapeau held various executive positions at BioMarin Pharmaceutical. He holds a BS in mechanical engineering and an MBA from Stanford University.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.